眾生藥業(002317.SZ)與愛爾眼科簽署《戰略合作框架協議》
格隆匯10月22日丨眾生藥業(002317.SZ)公佈,公司於2019年10月22日與愛爾眼科醫院集團股份有限公司(以下簡稱“愛爾眼科”)簽署了《戰略合作框架協議》。
公司與愛爾眼科簽署本戰略合作框架協議,建立密切、可持續發展的合作關係,充分挖掘和發揮雙方各自核心資源優勢,實現優勢互補和業務聯動發展,共同促進技術、產品與服務的延伸和發展。通過本次合作,實現雙方未來在產品研發、產供合作方面創造更大的合作商業價值,符合公司和全體股東的利益,有利於公司持續健康穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.